CytomX Therapeutics Receives $20,000,000 Series C Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a9a08b9f-defc-4822-b86a-76b90486f163
Date
1/6/2015
Company Name
CytomX Therapeutics
Mailing Address
343 Oyster Point Blvd. South San Francisco, CA 94080 USA
Company Description
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies.
Website
http://www.cytomx.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Series C
Proceeds Purposes
The proceeds from this financing will help enable CytomX to advance our proprietary pipeline of Probody Drug Conjugates and Probodies against cancer immunotherapy checkpoint targets towards the clinic, while we also pursue Probody applications with bispecific antibodies and engineered T-cell therapies.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor